文献速递肿瘤 PET/CT核素与放射性配体治疗

转移性前列腺癌中18F-DCFPyL PET/CT定量测量的可重复性

Repeatability of Quantitative 18F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer.
PubMed 文献 · J Nucl Med · 2020-01-10

本研究前瞻性纳入12例转移性前列腺癌患者(最终分析10例),每例接受2次全身18F-DCFPyL PET/CT扫描(中位剂量317 MBq,摄取时间120 min,中位间隔4天)。基于36个PET阳性病灶分析显示,各定量指标可重复性较高(组内相关系数均≥0.97),患者层面总肿瘤体积的可重复性高且不受不同图像重建影响。

要点

  • 18F-DCFPyL PET/CT定量指标可重复性较高,组内相关系数均≥0.97。
  • 病灶层面SUVmean、SUVpeak、SUVmax的可重复性系数分别为24.4%、25.3%、31.0%。
  • 患者层面总肿瘤体积的可重复性系数为17.0%,且不受不同图像重建影响。

核心结论

  • 18F-DCFPyL摄取测量具有较高的可重复性,可用于未来治疗反应评估研究的临床验证。
  • 患者层面的总肿瘤体积因可重复性高且对不同图像重建稳健,可能更适合多中心研究。

研究设计与样本

  • 前瞻性纳入12例转移性前列腺癌患者,其中2例被排除于最终分析之外。
  • 每例患者接受2次全身18F-DCFPyL PET/CT扫描(中位剂量317 MBq;摄取时间120 min),中位间隔4天(范围1-11天)。
  • 采用半自动(等轮廓线法)肿瘤勾画,衍生基于病灶的指标:平均、峰值和最大肿瘤与血池比值;按体重归一化的SUVmean、SUVpeak和SUVmax;肿瘤体积;总病灶摄取。
  • 还衍生基于患者的总肿瘤体积(PSMA阳性肿瘤体积之和)和总肿瘤负荷(所有病灶总病灶摄取之和)。
  • 使用可重复性系数和组内相关系数分析可重复性,并评估点扩散函数图像重建对摄取指标可重复性的影响。

主要发现

  • 共分析36个18F-DCFPyL PET阳性病灶(每例患者≤5个病灶)。
  • 平均、峰值和最大肿瘤与血池比值的可重复性系数分别为31.8%、31.7%和37.3%。
  • SUVmean、SUVpeak和SUVmax的可重复性系数分别为24.4%、25.3%和31.0%。
  • 所有组内相关系数均至少为0.97。
  • 单个病灶体积的可重复性系数为28.1%,总肿瘤体积为17.0%;基于SUVmean和平均肿瘤与血池比值计算的总肿瘤负荷可重复性系数分别为23.2%和33.4%。

关键数值与推荐

  • 平均肿瘤与血池比值的可重复性系数为31.8%,峰值肿瘤与血池比值为31.7%,最大肿瘤与血池比值为37.3%。
  • SUVmean的可重复性系数为24.4%,SUVpeak为25.3%,SUVmax为31.0%。
  • 所有组内相关系数均至少为0.97。
  • 单个病灶体积的可重复性系数为28.1%,总肿瘤体积为17.0%。
  • 基于SUVmean的总肿瘤负荷可重复性系数为23.2%,基于平均肿瘤与血池比值的总肿瘤负荷可重复性系数为33.4%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Quantitative evaluation of radiolabeled prostate-specific membrane antigen (PSMA) PET scans may be used to monitor treatment response in patients with prostate cancer (PCa). To interpret longitudinal differences in PSMA uptake, the intrinsic variability of tracer uptake in PCa lesions needs to be defined. The aim of this study was to investigate the repeatability of quantitative PET/CT measurements using 18F-DCFPyL ([2-(3-(1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid], a second-generation 18F-PSMA-ligand) in patients with PCa. Methods: Twelve patients with metastatic PCa were prospectively included, of whom 2 were excluded from final analyses. Patients received 2 whole-body 18F-DCFPyL PET/CT scans (median dose, 317 MBq; uptake time, 120 min) within a median of 4 d (range, 1-11 d). After semiautomatic (isocontour-based) tumor delineation, the following lesion-based metrics were derived: mean, peak, and maximum tumor-to-blood ratio; SUVmean, SUVpeak, and SUVmax normalized to body weight; tumor volume; and total lesion uptake (TLU). Additionally, patient-based total tumor volume (TTV) (sum of PSMA-positive tumor volumes) and total tumor burden (TTB) (sum of all lesion TLUs) were derived. Repeatability was analyzed using repeatability coefficients (RC) and intraclass correlation coefficients. Additionally, the effect of point-spread function (PSF) image reconstruction on the repeatability of uptake metrics was evaluated. Results: In total, 36 18F-DCFPyL PET-positive lesions were analyzed (≤5 lesions per patient). The RCs for mean, peak, and maximum tumor-to-blood ratio were 31.8%, 31.7%, and 37.3%, respectively. For SUVmean, SUVpeak, and SUVmax, the RCs were 24.4%, 25.3%, and 31.0%, respectively. All intraclass correlation coefficients were at least 0.97. Tumor volume delineations were quite repeatable, with an RC of 28.1% for individual lesion volumes and 17.0% for TTV. TTB had an RC of 23.2% and 33.4% when based on SUVmean and mean tumor-to-blood ratio, respectively. Small lesions (<4.2 cm3) had worse repeatability for volume measurements. The repeatability of SUVpeak, TLU, and all patient-level metrics was not affected by PSF reconstruction. Conclusion:18F-DCFPyL uptake measurements are quite repeatable and can be used for clinical validation in future treatment response assessment studies. Patient-based TTV may be preferred for multicenter studies because its repeatability was both high and robust to different image reconstructions.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Jansen BHE, Cysouw MCF, Vis AN, et al. Repeatability of Quantitative 18F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer. J Nucl Med. 2020. PMID: 31924729. doi:10.2967/jnumed.119.236075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。